Medical College of Wisconsin
CTSIResearch InformaticsREDCap

CURRICULUM VITAE

Siegfried Janz MD
Professor
Department of Medicine
Division of Hematology and Oncology - Medicine

OFFICE ADDRESS:
MACC Fund Research Center
8701 Watertown Plank Rd
Milwaukee, WI 53226

EDUCATION:
1976 - 1982 Master of Medicine, University of Leipzig Medical School, Germany
1982 - 1986 Clinical Immunology Resident, University of Leipzig Medical School, Germany
1982 M.D. Thesis Program, University of Leipzig Medical School, Germany
1983 - 1985 Medical Translator Training Program, University of Leipzig Medical School, Germany

FACULTY APPOINTMENTS:
1982 - 1988 Staff Physician-Scientist, Institute of Clinical Immunology, Medical School Leipzig, Germany
1988 - 1992 Visiting Research, Laboratory of Genetics
1992 - 1995 Associate Visiting Research, National Cancer Institute, NIH Laboratory of Genetics
1995 - 2007 Scientist Investigator, National Cancer Institute, NIH Laboratory of Genetics
2007 - 2011 Professor on tenure track, Pathology, UI Carver College of Medicine
2011 - 2018 Tenured Professor, Pathology, UI Carver College of Medicine
2018 - Present Tenured Professor, Medicine, Medical College of Wisconsin, Milwaukee, WI

SPECIALTY BOARDS AND CERTIFICATION:
Certificates
Issued By Issue DateExpiration
Medical Translator English-German
1985
None
Board Certification Clinical Immunology
1986
None
D.Sc. degree (Venia legendi, Dr. med. habil)
1995
None
    

Licensure
Number Issue DateExpiration
Physician, Leipzig, Saxony, Germany
62/82
1982
None
MD
1985
None
Clinical Immunologist, Leipzig, Saxony, Germany
33/87
1987
None
    

AWARDS AND HONORS:
1980 Best Student Award, Leipzig University Medical School
1981 Wilhelm Pieck National Scholarship, Germany
1985 Visiting Scholarship, Ministry of Technology and Science, Helsinki and Oulo, Finland
1997 Travel Award, International Meeting on Genetics of Radiation Response, Munich, Germany
1998 Intramural Research Award , Division of Basic Sciences
1999 Travel Award, VII International Myeloma Meeting, Stockholm, Sweden
1999 NIH commendation for 10 years of meritorious service
2001 Travel Award, EURESCO Conference on “B cells in Health and Disease, Acquafredda di Maratea, Italy
2001 FARE (Fellow Award for Research Excellence)
2002 FARE (Fellow Award for Research Excellence)
2003 FARE (Fellow Award for Research Excellence)
2004 NIH commendation for 15 years of meritorious service
2005 Keynote Lecture, Annual Meeting of the Korean Association for Laboratory Animal Sciences, South Korea
2006 Alfried Krupp Scholarship in Tumor Biology, Germany
2006 Marie Curie Scholarship, European School of Hematology (not accepted because of scheduling conflicts)
2009 Donald D. Dorfman Award for Basic Lymphoma Research
2018 Endowed Professor of Cancer Research, CCOM, UI
2018 William G. Schuett, Jr., Multiple Myeloma Endowed Chair

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:
2017 - Present NCI Cancer Genetics Study Section (Standing membership (for 4-year term))
AACR - American Association for Cancer Research (Member)
AAAS - American Association for the Advancement of Science (Member)
ASH - American Society of Hematology (Member)

EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:
Journal Review
2016 - 2018 Multiple Myeloma Research Foundation (MMRF); Kay Kendall Leukaemia Fund, a UK charity; Polish National Science Centre – Preludium Program
Ad-Hoc Reviewer
2002 - 2003 CancerCare Manitoba, Canada; ASPERA Foundation, Boston, MA; Dutch Cancer Society
2005 - 2006 Israel Science Foundation; AICR (Association for International Cancer Research, Scotland)
2008 - 2009 Multiple Myeloma Research Foundation (MMRF); MMRF
2010 - 2012 American Society of Hematology Annual Meeting; Coordinating Reviewer, Section 651A; Myeloma – Biology and Pathophysiology, excluding Therapy
2012 - 2014 Qatar National Research Fund (QNRF); MMRF; QNRF; UK Academy of Medical Sciences, Clinical Lecturer Starter Grant Program; QNRF; Polish National Science Centre – SONATA Program
2014 - 2015 Multiple Myeloma Research Foundation (MMRF); QNRF; MMRF Senior Research Award (SRA) Program; MMRF Research Fellow Award (RFA) Program; Polish National Science Centre – Symfonia 3 Program
2018 Polish National Science Centre – Preludium & Sonata Programs; Program Evaluation of NIH Peer Review Processes: The Role of Anonymization
American Journal of Pathology; BioMed Central: Cancer; BioMed Central: Cell Biology; BioMed Central: Molecular Cancer; Blood; Cancer Research; Cell Growth & Differentiation
Genes, Chromosomes and Cancer; Gene Therapy; International Journal of Cancer; Journal of Clinical Investigation; Leukemia; Leukemia & Lymphoma; Leukemia Research
Molecular Cancer Therapeutics; Molecular & Cellular Biology; Oncogene, Oncotarget; Proceedings of the National Academy of Sciences; Trends in Genetics

NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:
2007 Grant Review Service, NCI Subcommittee I for Career Development (Byrd committee), NIH Committee
2009 - 2010 2009 PhD Free Radicals Program, Janice Wang (Knudson lab); 2010 MS Immunol Prog, Delila Peri (Weiner Lab);, CCOM Committee Service
2009 Bioinformatics Shared Resource Ovesight Committee, HCCC Committee Service
2010 - 2011 Grant Review Service, Special Emphasis Panel/SRG 2010/08 ZRG1 OBT-A (55); Tumor Microenvironment (TME) Study Section; NCI Lymphoma SPORE, NIH Committee
2011 - 2012 K01 mentor – Steve Polyak, Internal Med; K01 mentor – Ann Simons, Path; K99 mentor – Weizhou Zhan, Path, HCCC Committee Service
2011 MS Path Program, Daniel Samar (Klutts Lab); PhD Immunol Prog, Wai Wai Lin (Bishop Lab); PhD MCB Prog, Lauren Workman (Habelhah Lab); Assis Prof on tenure track, Apollina Goel; Assis Prof on tenure track, David Motto, CCOM Committee Service
2011 - Present Grant Review Service, DoD Congressionally Directed Medical Research Programs Peer Reviewed Cancer Research Program Discovery Award, W81XWH-11-PRCRP-DA, Department of Defense
2012 - 2013 PhD Immunol Prog, Ann Janowski (Sutterwala Lab);PhD Immunol Prog, Rahul Vijay (Perlman Lab) – Comps Exam Co-Chair; PhD Immunol Prog, Mahmood Bilal (Houtman Lab) – Comps Exam Co-Chair; PhD Immunol Prog, Farrah Steinke (Xue Lab) – Comps Exam Co-Chair; PhD Immunol Prog, Farrah Steinke (Xue Lab) – Comps Exam Co-Chair, CCOM Committee Service
2012 Grant Review Service, DoD Congressionally Directed Medical Research Programs Peer Reviewed Cancer Research Program Blood cancers, Department of Defense
2015 Grant Review Service, NCI F09A-D IAM Fellowship Review Committee (03/15); NCI ZCA1 SRB-X (O1): NCI Omnibus R03 & R21 Review Committee (06/15); NCI F09A-D IAM Fellowship Review Committee (09/15); NCI ZRG1 F09A-D Oncology Fellowship Review Committee (11/15), NIH Committee
2016 - 2017 PhD Immunol Prog, Derek Danahy – Comps Exam Co’ee; PhD Immunol Prog, Megan Stoley – Comps Exam Co’ee;PhD Immunol Prog, Nurbek Mambetsariev (Bishop Lab); Quinquennial review of Department of Obstetrics and Gynecology, CCOM, UI; PhD Immunol Prog, Amy Whillock (Bishop Lab), CCOM Committee Service
2016 Grant Review Service, NCI F09A-D IAM Fellowship Review Committee (03/16); NCI F09A-D IAM Fellowship Review Committee (07/16); NCI Cancer Genetics Study Section (10/16); NCI F09A-D IAM Fellowship Review Committee (11/16), NIH Committee
2017 Grant Review Service, NCI Cancer Genetics Study Section (02/17); NCI Omnibus R21/R03 Review Committee (03/17); NCI F09A-D IAM Fellowship Review Committee (03/17); NCI Cancer Genetics Study Section (06/17); NCI F09A-D IAM Fellowship Review Committee (07/17); NCI Cancer Genetics Study Section (10/17), NIH Committee
2018 Grant Review Service, NCI Cancer Genetics Study Section (02/18); NCI Cancer Genetics Study Section (06/18); NCI Cancer Genetics Study Section (10/18), NIH Committee

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:
Prior
Peer Review
Source:
Division of Basic Sciences, NCI
Role & Effort:
Principal Investigator
PI:
Janz, Siegfried
Dates:
1994 - 1995
  
Source:
Intramural NIH support through National Cancer Institute (NCI)
Role & Effort:
Principal Investigator
PI:
Janz, Siegfried
Dates:
1995 - 2006
  
Source:
Center for Cancer Research, NCI
Role & Effort:
Principal Investigator
PI:
Janz, Siegfried
Dates:
1996 - 2006
  
Title:
Determination of the three-dimensional fine structure of the BALB/c plasmacytoma-typical T(12;15) translocation by confocal fluorescence microscopy in spectral precision distance mode.
Source:
NCI/NIH Research Award on top of automatic intramural funding
Role & Effort:
Principal Investigator (effort percentage not defined)
PI:
Janz, Siegfried
Dates:
09/1998 - 08/2001
Direct Funds:
$300,000
  
Source:
5 P30 CA086862-09 (Weiner), NIH/NCI, Cancer Center Support Grant (CCSG)
Role & Effort:
Cancer Genetics and Computational Biology Program Leader
Dates:
07/14/2000 - 06/30/2010
  
Title:
Lymphoma Specialized Program of Research Excellence (SPORE)
Source:
5 P50 CA097274-07 (Weiner), NIH/NCI
Role & Effort:
SPORE Developmental Project Principal Investigator
PI:
Janz, Siegfried
Dates:
02/01/2008 - 01/31/2010
  
Title:
iMycC and Bcl-XL Transgenic Mice
Source:
Sponsored Research Agreement (Janz), Millennium Pharmaceuticals, Inc.
Role & Effort:
Principal Investigator
PI:
Janz, Siegfried
Dates:
03/24/2008 - 03/23/2009
  
Title:
NCKU-Functional Genomic Approach for Discovery of Molecular Mechanisms and Therapeutic Targets (DMMaTT) of Human Cancer
Source:
NCKU (Janz), National Cheng Kung University
Role & Effort:
Principal Investigator
PI:
Janz, Siegfried
Dates:
07/01/2008 - 08/31/2008
  
Title:
Preclinical evaluation of new treatments for childhood B lymphocyte-derived non-Hodgkin lymphoma (B-NHL)
Source:
Aiming for a Cure Foundation Grant (Janz), The University of Iowa Holden, Comprehensive Cancer Center
Role & Effort:
Principal Investigator
PI:
Janz, Siegfried
Dates:
10/01/2008 - 09/30/2010
  
Title:
Transgenic mouse model of human LMP1/MYC
Source:
Carver Collaborative Pilot Grant (Janz), The University of Iowa, Carver College of Medicine
Role & Effort:
Principal Investigator
PI:
Janz, Siegfried
Dates:
02/01/2009 - 01/31/2011
  
Title:
Preclinical validation of IL-6 for translational myeloma research
Source:
MMRF, Multiple Myeloma Research Foundation
Role & Effort:
Principal Investigator
PI:
Janz, Siegfried
Dates:
12/01/2009 - 11/30/2011
  
Source:
Cancer Genetics5 P30 CA086862-09 (Weiner), NIH/NCI
Role & Effort:
Cancer Genomics and Cell Growth Program Co-Leader
Dates:
07/01/2010 - 06/30/2014
  
Title:
Defining genetic pathways of plasma-cell neoplasia
Source:
1R01CA151354-01, NIH/NCI
Role & Effort:
Principal Investigator
PI:
Janz, Siegfried
Dates:
07/19/2010 - 05/31/2015
  
Source:
IWMF 2010-1, International Waldenström’s Macroglobulinemia Foundation, Transgenic mouse model of Waldenström’s Macroglobulinemia
Role & Effort:
Principal Investigator
PI:
Janz, Siegfried
Dates:
08/01/2010 - 07/31/2012
  
Source:
P50 CA97274 (Weiner), NIH/NCI, UI/MC Lymphoma SPORE Career Development Award
Role & Effort:
Trainee
Dates:
07/01/2013 - 06/30/2014
  
Title:
Leica LMD 7000 Laser Capture Microdissection Microscope
Source:
1S10OD01316-01 (Janz), NIH/OD
Role & Effort:
Principal Investigator
PI:
Janz, Siegfried
Dates:
07/11/2013 - 07/10/2014
  
Source:
CCOM Bridge Funding (Janz), University of Iowa Carver College of Medicine
Role & Effort:
Principal Investigator
PI:
Janz, Siegfried
Dates:
07/01/2015 - 06/30/2016
  
Title:
NEK2 plays a critical role in myeloma minimal residual disease
Source:
Multiple Myeloma Research Foundation (Zhan), Senior Research Award Program
Role & Effort:
Co-investigator
Dates:
10/01/2015 - 09/30/2018
  
Title:
Oncolytic therapy of myeloma
Source:
Investigator-initiated research project (Janz), Omnis Pharma, Rochester, MN
Role & Effort:
Principal Investigator
PI:
Janz, Siegfried
Dates:
11/01/2015 - 03/20/2016
  
Title:
BTK is a therapeutic target in MMSC
Source:
Investigator-initiated research project (Janz), Pharmacyclics LLC, Sunnyvale, CA
Role & Effort:
Principal Investigator
PI:
Janz, Siegfried
Dates:
02/25/2016 - 02/24/2017
  
Source:
American Society of Hematology (Janz), Bridge Grant Program
Role & Effort:
Principal Investigator
PI:
Janz, Siegfried
Dates:
03/01/2016 - 02/28/2017
  
Title:
Transgenic mouse model of human KSHV-associated B-lymphocyte disorders
Source:
Carver Trust Medical Research Initiative (Janz)
Role & Effort:
Principal Investigator
PI:
Janz, Siegfried
Dates:
02/01/2017 - 01/31/2019
  

INVITED LECTURES/WORKSHOPS/PRESENTATIONS:
International
Department of Immunology, Erlangen University, Germany, 1992
Environmental Research Center, Leipzig, Germany, 1993
German Society for Immunology, 24th Annual Meeting, Leipzig, Germany, 1993
Institute for Molecular Biology and Tumor Genetics, Munich, 1994
Lymphocyte Neoplasia and DNA Rearrangements in the Immune System, EMBO Workshop, 13th Workshop on Mechanism of B Cell, Neoplasia, Basel, Switzerland, 1995
Max Delbrück Center, Berlin, Germany, 1997
Graduate College, Leipzig University, Leipzig, Germany, 1997
Institute of Molecular Biology and Tumor Genetics, GSF, Munich, Germany, 1998
Mechanisms in B Cell Neoplasia, 15th Workshop, Basel, Switzerland, 1998
Karolinska Institute, Stockholm, Sweden, 1999
German Society for Experimental Oncology, Annual Meeting, Heidelberg, Germany, 1999
Cellular and Molecular Biology, 3rd World Congress, Jena, Germany, 2000
B cells in Health and Disease, EURESCO Conference, Acquafredda di Maratea, Italy, 2001
University of Greifswald, Germany, 2002
Institute for Molecular Biology and Tumor Genetics, Munich, Germany, 2002
University of Heidelberg, Germany, 2002
University of Greifswald, Greifswald, Germany, 2003
IXth Multiple Myeloma Meeting, Salamanca, Spain, 2003
Institute for Molecular Biology, Marburg, Germany, 2003
Manitoba Institute of Molecular Biology, Winnipeg, Canada, 2003
Institute of Biochemistry and Molecular Biology, Ernst Moritz Arndt University of Greifswald, Greifswald, Germany, 2005
Heidelberger Myelomtage, Workshop on Multiple Myeloma, Heidelberg, Germany, 2005
Korean Association for Laboratory Animal Science, Annual Meeting, Seoul, Korea, 2005
10th International Myeloma Workshop, Sydney, Australia, 2005
Institute for Cancer Therapy, Bradford University, United Kingdom, 2006
Division of Cancer Sciences, University of Southampton, United Kingdom, 2006
Department of Pathology, University of Berne, Switzerland, 2006
University of Geneva Medical School, Geneva, Switzerland, 2006
Institute of Biochemistry and Molecular Biology, Ernst Moritz Arndt University of Greifswald, Greifswald, Germany, 2006
Institute of Biochemistry and Molecular Biology, Ernst Moritz Arndt University of Greifswald, Greifswald, Germany, 2007
Institute of Molecular Medicine, National Chen Kung University, Tainan, Taiwan, 2008
University of Würzburg Medical School, Würzburg, Germany, 2010
University of Würzburg Medical School, Würzburg, Germany, 2012
Lymphoma & Myeloma, The First Union Summit Forum, Tianjin, China, 2013
Department of Hematology, West China Hospital, Sichuan University, Chengdu, China, 2015
Department of Hematology, Jinan University, Guangzhou, China, 2015
5. Heidelberger Myelomtage, 5th Workshop on Multiple Myeloma, German Cancer Research Centre (DKFZ) and National Tumor Centre (NTC), Heidelberg, Germany, 2015
Peking University People’s Hospital and Peking University Institute of Hematology, Beijing, China, 2015
Institute of Hematology and Blood Diseases, Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC), Tianjin, China, 2015
The Myeloma and Lymphoma Center, Changzheng Hospital, The Second Military Medical University, Shanghai, China, 2015
Nanjing University of Chinese Medicine, Nanjing, China, 2016
Myeloma Section, Clinic of Internal Medicine V, University of Heidelberg and National Tumor Centre (NTC), Heidelberg, Germany, 2016
6. Heidelberger Myelomtage, 6th Workshop on Multiple Myeloma, German Cancer Research Centre (DKFZ) and National Tumor Centre (NTC), Heidelberg, Germany, 2017
HemOnc / Myeloma departments at Tangdu Hospital and Xijing Hospital, Xi’an City, Shaanxi Province, PRC, 2017
3rd Myeloma Summit, Chinese Medical Society, Guangzhou City, Guangdong Province, PRC, 2017
Multiple Myeloma and other Blood Cancers, 3rd Symposium on Holistic Integrative Medicine, Nanjing, Jiangsu, PRC, 2018
 
National
Annual Tumor Cell Biology Meeting, Bethesda, MD, 1994
Mechanisms in B Cell Neoplasia, 12th Workshop, Bethesda, MD, 1994
Laboratory of Medical and Molecular Genetics, Division of Cell and Gene Therapies, CBER, FDA, Bethesda, MD, 1995
Mechanisms in B Cell Neoplasia, 14th Workshop, Bethesda, MD, 1996
Laboratory of Immunopathology, NIAID, NIH, Bethesda, MD, 1996
International Burkitt Lymphoma Meeting, Annapolis, MD, 1997
Arkansas Cancer Research Center, Little Rock, AR, 1999
Beckman Center, Stanford Medical School, Stanford, CA, 2000
Plasma Cell Tumor Formation, Workshop, Bethesda, MD, 2001
Genomics Meets Nanoscience, The Jackson Laboratory, Bar Harbor, ME, 2001
Genetics Branch, Center for Cancer Research, NCI, NIH, 2001
Summer Student Research Conference, CCR, NCI, 2001
Animal Models for Cancer Prevention Retreat, CCR, NCI, Frederick, MD, 2001
Cell Signaling Technology, Inc., Beverly MA, 2001
Genomics Meets Nanoscience II, The Jackson Laboratory, Bar Harbor, ME, 2002
Cell Signaling Technology, Inc., Beverly, MA, 2002
Laboratory of Pathology, Center for Cancer Research, NCI, 2002
Mouse Models in Cancer, AACR Special Conference, Lake Buena Vista, FL, 2003
Metabolism Branch, Center for Cancer Research, NCI, 2003
Cell Signaling Technology, Inc., Beverly, MA, 2003
Plasma Cell Tumor Formation, Workshop, Bethesda, MD, 2003
Mouse Genetics Retreat, CCR, NCI, 2004
20th Oncogene Meeting, Frederick, MD, 2004
Mouse Genetics Retreat, CCR, NCI, 2005
B cell workshop, Metabolism Branch, Center for Cancer Research, NCI, 2005
Ohio State University, Columbus, OH, 2006
2006 Department of Pathology, University of Iowa, Iowa City, IA, 2006
Mechanisms and Consequences of Chromosomal Translocation, NCI Workshop, Warrenton, VA, 2006
The Jackson Laboratory, Bar Harbor, ME, 2006
Institute of Molecular Medicine, National Chen Kung University, Tainan, Taiwan, 2006
Millenniun Pharmaceuticals, Inc., Cambridge, MA, 2007
Hematology-Oncology Grand Rounds, The University of Iowa Carver College of Medicine, Iowa City, IA, 2008
UI/MC Lymphoma SPORE retreat, Rochester, MN, 2008
The University of Iowa Immunology Graduate Program, Iowa City, IA, 2008
Department of Pharmacology, University of Iowa, Iowa City, IA, 2009
University of Iowa Biosciences Program, Iowa City, IA, 2010
Interdisciplinary Graduate Program in Immunology, University of Iowa, Iowa City, IA, 2010
Department of Microbiology, University of Virginia, Charlottesville, VA, 2010
Laboratory of Immunopathology, NIAID, NIH, Rockville, MD, 2010
Laboratory of Tumor Biology and Genetics, NCI, NIH, Bethesda, MD, 2010
Department of Pathology Grand Rounds, University of Iowa, Iowa City, IA, 2010
Education Forum, ternational Waldenström Macroglobulinemia Foundation, Minneapolis, MN, 2011
Division of Hematologic Malignancies, University of Utah School of Medicine, Salt Lake City, UT, 2011
Department of Pediatrics, Division of Hematology/Oncology, University of Iowa Carver College of Medicine, Iowa City, IA, 2014
Multiple Myeloma, Workshop, Genetics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, 2014
Pharmacyclics, Inc., Sunnyvale, CA, 2015
Department of Pathology, University of Florida, Gainesville, FL, 2017
 
Local
HemOnc, Medical College of Wisconsin, Milwaukee, WI, 2017
 

EXTRAMURAL STUDENTS, FACULTY, RESIDENTS, AND CLINICAL/RESEARCH FELLOWS MENTORED:
Medical Students
1986 Bernd Rassmann, Medical School Leipzig, Diploma thesis
1987 Ute Puhlmann, Medical School Leipzig, Diploma thesis
 
Graduate Students
Students Advised
09/1996 - 08/1997 Amanda King, National Cancer Institute, CRTA Fellow
09/1996 - 08/1998 Kevin Kelliher, National Cancer Institute, NCI Cancer Research Training Award (CRTA) Fellow
02/1999 - 02/2002 Lynne D. Rockwood, National Cancer Institute, CI Intramural Research Training Award (IRTA) Fellow
09/2005 - 08/2006 Sebastian Rutsch, National Cancer Institute, Volunteer
 
Postdoctoral Researchers
10/1992 - 10/1996 Jürgen R. Müller, Visiting Fellows sponsored by NIH Fogarty Program, University of Leipzig, Germany
01/1994 - 06/2023 Klaus Felix, Research Fellows sponsored by the NCI Center for Cancer Research Intramural Program, Institute for Molecular Biology and Tumor Genetics, Munich, Germany
10/1994 - 06/2001 Alexander L. Kovalchuk, Visiting Fellows sponsored by NIH Fogarty Program, University of Moscow, Russia
11/1997 - 10/2000 Sung Sup Park, Visiting Fellows sponsored by NIH Fogarty Program, KRIBB, Korea
04/2001 - 09/2003 Joong Su Kim, Visiting Fellows sponsored by NIH Fogarty Program, KRIBB, Korea
02/2002 - 10/2001 Liangping Peng, Visiting Fellows sponsored by NIH Fogarty Program, University of Beijing, China
02/2002 - 02/2005 Seong Su Han, Research Fellows sponsored by the NCI Center for Cancer Research Intramural Program, University of Seoul, Korea
09/2002 - 09/2004 Santiago Silva, Research Fellows sponsored by the NCI Center for Cancer Research Intramural Program, Karolinska Institute, Stockholm, Sweden
09/2003 - 12/2006 Seung Tae Chung, Visiting Fellows sponsored by NIH Fogarty Program, University of Seoul, Korea
09/2004 - 09/2006 Ki-Hwan Kim, Visiting Fellows sponsored by NIH Fogarty Program, University of Seoul; Visiting Fellow
10/2004 - 05/2006 Kenichi Fujita, Visiting Fellows sponsored by NIH Fogarty Program, NCI Japan, Tokyo
12/2004 - 12/2006 Makiko Takizawa, Visiting Fellows sponsored by NIH Fogarty Program, Kumamoto University, Japan
07/2007 - 08/2008 Dr. Hwa Kyung Yun; exchange research scholar
09/2007 - 07/2013 Dr. Van Tompkins, post-doctoral research scholar
12/2007 - 12/2008 Dr. Dong Ju Son; exchange research scholar
05/2009 - 08/2009 Kevin Peters; IDGP Summer Undergraduate Progam
06/2009 - 08/2009 Kaylene Baugh; DoD/Lincoln Univ Summer Res Prog
03/2010 - 01/2015 Timothy R Rosean; Ph.D. Immunol Grad Prog
06/2010 - 08/2010 Stephan Sangster; DoD/Lincoln Univ Summer Res Prog
09/2010 - 08/2012 Samuel Lifton; Ph.D. Immunol Grad Prog
09/2010 - 07/2013 Kaylia Duncan; MS Pathology Prog
03/2011 - 07/2012 Natalie Kamberos; Pediatric Hem/Onc Fellowship
06/2015 - 08/2015 Shelby Foor; SURP / Immunology Prog.
09/2015 - 03/2016 Chunyan Gu, PhD
07/2017 - 08/2023 Michael D. Pisano; Ph.D. Immunol Grad Prog
07/2017 - 06/2019 Krista A. Lingle-Mullen Duncan; MS Pathology Prog
08/2017 - 07/2021 Fumou Sun; postdoctoral research scholar
04/2018 - 07/2021 Yan Cheng; predoctoral research scholar
 

AREAS OF RESEARCH INTEREST AND CURRENT PROJECTS:
Cancer biology, genetics and cytogenetics; Experimental cancer pathology; Inflammation-dependent carcinogenesis; Cancer-associated chromosomal translocations; Proto-oncogenes such as MYC (c-myc); Neoplasms derived from mature B lymphocytes and plasma cells; Transgenic mouse models of human B lineage neoplasms; Innovative, targeted approaches for treatment and prevention of B cell and plasma cell tumors such as NHL and multiple myeloma

OTHER CONTRIBUTIONS TO INSTITUTIONAL PROGRAMS:
UI Carver College of Medicine 2007 – 2015 Member, Executive Committee, Holden Comprehensive Cancer Center (HCCC) 2007 – 2009 Leader, Cancer Genetics and Computational Biology Program, HCCC 2008 – 2011 Leader, Tumor Biology Group, Dept Pathol, UI CCOM 2009 – 2015 Co-leader, Cancer Genomics and Cell Growth Program, HCCC 2007 – present Member, Tumor Biology Group, Dept Pathol, UI CCOM 2008 – present Faculty member, UI Immunology Graduate Program 2009 – present Faculty member, UI Biosciences Graduate Program 2013 – present Faculty Coordinator, Tumor Biology Group, Dept Pathol 2015 – present Member, Cancer Genes and Pathways Program, HCCC
Medical School Leipzig Development of sponsored research agreement with Labsytems, Inc., Helsinki, Finland, concerning Bioscreen Analyzer SystemTM Membership and activities in Society for Immunology and Chamber of Physicians and Surgeons, Saxony
Employee Invention Reports Concerning Transgenic Mouse Strains E-016-98/0 - Congenic mouse strains for in vivo mutagenesis studies E-286-01/0 - Tet-off/Myc mice E-287-01/0 - BALB/c.H2-Ld-hu-IL-6 congenic mice E-288-01/0 - E-Myc knock-in mice (iMycE) E-289-01/0 - C-Myc knock-in mice (iMycC) E-290-01/0 - Ig-Myc transgenic mice (-MYC) E-291-01/0 - Ig-Myc transgenic mice (-MYC) E-108-02/0 - LIZ congenic mouse strains E-109-02/0 - pUR288 congenic mouse strains E-160-03/0 - C-Myc knock-in mice (iMycC)

TEACHING:
Medical School Leipzig Seminars and lectures on clinical immunology and immunobiology for medical students National Cancer Institute No formal teaching assignments Planning, organizing, and executing numerous small-group research seminars for students and postdoctoral trainees Planning, organizing, and executing branch- and laboratory-wide research seminars with invited speakers from the NIH intramural program, US-based scientists outside NIH, or researchers from abroad UI Carver College of Medicine 148:251 Principles in Medical Immunology Case Analysis, Small Group Facilitator Spring 2008-2012 069:270 Pathogenesis of Major Human Diseases, Small Group Facilitator Spring 2008-2015 156:201 Principles in Molecular and Cell Biology, Small Group Facilitator Fall 2008-2012 069:133 Introduction to Human Pathology Lecturer Fall 2008-2015 148:221 Advanced Topics in Immunology, Small Group Facilitator Fall 2009-2011 069:260 Translational histopathology Lecturer Fall 2009-2011 142:240 MCB Inflammatory Cell Signaling Lecturer and Small Group Facilitator Fall 2014-2016


BIBLIOGRAPHY
Refereed Journal Publications/Original Papers
1. Janz S, Püschel W, Raabe F, Storch H. Induction of plasma cell tumours with 2,6,10,14-tetramethylpentadecane (pristane) and paraffin oil (paraffinum perliquidum) in BALB/c mice simultaneously exposed to sustained antigenic stimulation with bovine serum albumin (BSA). Arch Geschwulstforsch. 1987;57(1):25-30.
2. Janz S, Herzschuh R, Storch H. Evidence for high purity of a commercial pristane (2,6,10,14-tetramethylpentadecane) preparation used for plasmocytoma induction in BALB/c mice. Exp Pathol. 1987;31(4):253-5.
3. Janz S, Huttunen T, Herzschuh R, Storch H. Genotoxicity assessment of the plasmacytomagenic agent pristane (2.6.10.14-tetramethylpentadecane) and four related alkanes by the SOS chromotest. Arch Geschwulstforsch. 1988;58(2):73-8.
4. Janz S, Wolff G, Storch H. SOS chromotest, a quantitative short-term bacterial assay for the detection of genotoxic compounds in an automated version adapted to Bioscreen Analyzer System. Zentralbl Mikrobiol. 1988;143(8):645-9.
5. Klimm W, Janz S, Gabert A. [Experimental research on the genotoxicity of various root canal antiseptics in the SOS chromotest]. Zahn Mund Kieferheilkd Zentralbl. 1989;77(2):128-30.
6. Janz S, Birkenfeld T, Herzschuh R, Storch H. Gas chromatographic-mass spectrometric investigation of four commercial pristane (2.6.10.14-tetramethylpentadecane) preparations used for plasmacytoma induction in BALB/c mice. Arch Geschwulstforsch. 1989;59(6):415-22.
7. Janz S, Wolff G, Huttunen T, Raabe F, Storch H. Quantitation of the relationship between tester cell number inoculated and SOS-inducing potency of 4-nitroquinoline-1-oxide (4-NQO) in an automated version of the SOS chromotest. J Basic Microbiol. 1989;29(7):403-11.
8. Janz S, Rassmann B, Raabe F, Storch H. [Histologic studies of paraproteinemic nephropathy in BALB/c mice with mineral oil-induced plasmacytoma]. Z Urol Nephrol. 1989 Dec;82(12):671-8.
9. Janz S, Raabe F, Wolff G. Application of an alternative approach for using the SOS chromotest to screen complex indeterminate mixtures. Zentralbl Mikrobiol. 1990;145(3):177-82.
10. Raabe F, Janz S, Wolff G. The effect of non-ionic surfactants on the SOS-inducing potency of 4-nitroquinoline-1-oxide in Escherichia coli PQ37. J Basic Microbiol. 1990;30(6):435-42.
11. Shacter E, Lopez RL, Beecham EJ, Janz S. DNA damage induced by phorbol ester-stimulated neutrophils is augmented by extracellular cofactors. Role of histidine and metals. J Biol Chem. 1990 Apr 25;265(12):6693-9.
12. Janz S, Shacter E. A new method for delivering alkanes to mammalian cells: preparation and preliminary characterization of an inclusion complex between beta-cyclodextrin and pristane (2,6,10,14-tetramethylpentadecane). Toxicology. 1991;69(3):301-15.
13. Janz S, Brede O, Müller J. The reaction of pristane (2,6,10,14-tetramethylpentadecane) with radiolytically generated reactive oxygen intermediates results in a stable genotoxic compound as assessed by the SOS chromotest. Carcinogenesis. 1991 Jul;12(7):1241-6.
14. Gawrisch K, Janz S. The uptake of pristane (2,6,10,14-tetramethylpentadecane) into phospholipid bilayers as assessed by NMR, DSC, and tritium labeling methods. Biochim Biophys Acta. 1991 Dec 09;1070(2):409-18.
15. Müller J, Janz S. Assessment of oxidative DNA damage in the oxyR-deficient SOS chromotest strain Escherichia coli PQ300. Environ Mol Mutagen. 1992;20(4):297-306.
16. Janz S, Krumbiegel M, Gawrisch K. The fluidity of DOPC bilayers and membrane fractions prepared from murine plasmacytoma cells is unchanged after incorporation of pristane (2,6,10,14-tetramethylpentadecane) as assessed by fluorescence polarization analysis. Cancer Biochem Biophys. 1992 Nov;13(2):85-92.
17. Janz S, Shacter E. Activated murine neutrophils induce unscheduled DNA synthesis in B lymphocytes. Mutat Res. 1993 Jan;293(2):173-86.
18. Müller J, Janz S. Modulation of the H2O2-induced SOS response in Escherichia coli PQ300 by amino acids, metal chelators, antioxidants, and scavengers of reactive oxygen species. Environ Mol Mutagen. 1993;22(3):157-63.
19. Raabe F, Janz S, Wolff G, Merten H, Landrock A, Birkenfeld T, Herzschuh R. Genotoxicity assessment of waste products of aluminum plasma etching with the SOS chromotest. Mutat Res. 1993 Jul;300(2):99-109.
20. Janz S, Müller J, Shaughnessy J, Potter M. Detection of recombinations between c-myc and immunoglobulin switch alpha in murine plasma cell tumors and preneoplastic lesions by polymerase chain reaction. Proc Natl Acad Sci U S A. 1993 Aug 01;90(15):7361-5. PMCID: PMC47137
21. Müller JR, Potter M, Janz S. Differences in the molecular structure of c-myc-activating recombinations in murine plasmacytomas and precursor cells. Proc Natl Acad Sci U S A. 1994 Dec 06;91(25):12066-70. PMCID: PMC45377
22. Janz S, Gawrisch K, Lester DS. Translocation and activation of protein kinase C by the plasma cell tumor-promoting alkane pristane. Cancer Res. 1995 Feb 01;55(3):518-24.
23. Janz S, Shacter E. Disposition of the plasmacytomagenic alkane pristane (2,6,10,14-tetramethylpentadecane) in mice. Cancer Biochem Biophys. 1995 Jun;15(1):25-34.
24. Müller JR, Janz S, Goedert JJ, Potter M, Rabkin CS. Persistence of immunoglobulin heavy chain/c-myc recombination-positive lymphocyte clones in the blood of human immunodeficiency virus-infected homosexual men. Proc Natl Acad Sci U S A. 1995 Jul 03;92(14):6577-81. PMCID: PMC41561
25. Müller JR, Janz S, Potter M. Differences between Burkitt's lymphomas and mouse plasmacytomas in the immunoglobulin heavy chain/c-myc recombinations that occur in their chromosomal translocations. Cancer Res. 1995 Nov 01;55(21):5012-8.
26. Janz S, Roschke VV. Completion of the DNA sequence determination of the Igh2 locus of the mouse: the 5'-IA region. Immunogenetics. 1996;43(1-2):101-4.
27. Kovalchuk AL, Potter M, Janz S. DNA sequence analysis of the genetic recombination between Igh6 and Myc in an uncommon BALB/c plasmacytoma, TEPC 1194. Immunogenetics. 1996;44(2):151-6.
28. Müller JR, Jones GM, Potter M, Janz S. Detection of immunoglobulin/c-myc recombinations in mice that are resistant to plasmacytoma induction. Cancer Res. 1996 Jan 15;56(2):419-23.
29. Liyanage M, Coleman A, du Manoir S, Veldman T, McCormack S, Dickson RB, Barlow C, Wynshaw-Boris A, Janz S, Wienberg J, Ferguson-Smith MA, Schröck E, Ried T. Multicolour spectral karyotyping of mouse chromosomes. Nat Genet. 1996 Nov;14(3):312-5.
30. Müller JR, Jones GM, Janz S, Potter M. Migration of cells with immunoglobulin/c-myc recombinations in lymphoid tissues of mice. Blood. 1997 Jan 01;89(1):291-6.
31. Felix K, Potter M, Bornkamm GW, Janz S. In vitro mutagenicity of the plasmacytomagenic agent pristane (2,6,10,14-tetramethylpentadecane). Cancer Lett. 1997 Feb 26;113(1-2):71-6.
32. Felix K, Lin S, Janz S. Elevated mutant frequencies in gene lacI in splenic lipopolysaccharide blasts after exposure to activated phagocytes in vitro. Eur J Immunol. 1997 Sep;27(9):2160-4.
33. Kovalchuk AL, Müller JR, Janz S. Deletional remodeling of c-myc-deregulating chromosomal translocations. Oncogene. 1997 Nov 06;15(19):2369-77.
34. Felix K, Lin S, Bornkamm GW, Janz S. Tetravinyl-tetramethylcyclo-tetrasiloxane (tetravinyl D4) is a mutagen in Rat2lambda lacI fibroblasts. Carcinogenesis. 1998 Feb;19(2):315-20.
35. Felix K, Kelliher K, Bornkamm GW, Janz S. Association of elevated mutagenesis in the spleen with genetic susceptibility to induced plasmacytoma development in mice. Cancer Res. 1998 Apr 15;58(8):1616-9.
36. Felix K, Kelliher KA, Bornkamm GW, Janz S. Elevated mutant frequencies in lymphoid tissues persist throughout plasmacytoma development in BALB/c.lambdaLIZ mice. Cancer Res. 1999 Aug 01;59(15):3621-6.
37. Coleman AE, Kovalchuk AL, Janz S, Palini A, Ried T. Jumping translocation breakpoint regions lead to amplification of rearranged Myc. Blood. 1999 Jun 15;93(12):4442-4.
38. Kovalchuk AL, Mushinski EB, Janz S. Clonal diversification of primary BALB/c plasmacytomas harboring T(12;15) chromosomal translocations. Leukemia. 2000 May;14(5):909-21.
39. Coleman AE, Ried T, Janz S. Chromosomes 1 and 5 harbor plasmacytoma progressor genes in mice. Genes Chromosomes Cancer. 2000 Sep;29(1):70-4.
40. Kovalchuk AL, Qi CF, Torrey TA, Taddesse-Heath L, Feigenbaum L, Park SS, Gerbitz A, Klobeck G, Hoertnagel K, Polack A, Bornkamm GW, Janz S, Morse HC 3rd. Burkitt lymphoma in the mouse. J Exp Med. 2000 Oct 16;192(8):1183-90. PMCID: PMC2195876
41. Felix K, Kovalchuk AL, Park SS, Coleman AE, Ramsay ES, Qian M, Kelliher KA, Jones GM, Ried T, Bornkamm GW, Janz S. Inducible mutagenesis in TEPC 2372, a mouse plasmacytoma cell line that harbors the transgenic shuttle vector lambdaLIZ. Mutat Res. 2001 Jan 25;473(1):121-36.
42. Kovalchuk AL, Esa A, Coleman AE, Park SS, Ried T, Cremer CC, Janz S. Translocation remodeling in the primary BALB/c plasmacytoma TEPC 3610. Genes Chromosomes Cancer. 2001 Mar;30(3):283-91.
43. Hori M, Xiang S, Qi CF, Chattopadhyay SK, Fredrickson TN, Hartley JW, Kovalchuk AL, Bornkamm GW, Janz S, Copeland NG, Jenkins NA, Ward JM, Morse HC 3rd. Non-Hodgkin lymphomas of mice. Blood Cells Mol Dis. 2001;27(1):217-22.
44. Esa A, Coleman AE, Edelmann P, Silva S, Cremer CG, Janz S. Conformational differences in the 3-D nanostructure of the immunoglobulin heavy-chain locus, a hotspot of chromosomal translocations in B lymphocytes. Cancer Genet Cytogenet. 2001 Jun;127(2):168-73.
45. Kovalchuk AL, Kim JS, Park SS, Coleman AE, Ward JM, Morse HC 3rd, Kishimoto T, Potter M, Janz S. IL-6 transgenic mouse model for extraosseous plasmacytoma. Proc Natl Acad Sci U S A. 2002 Feb 05;99(3):1509-14. PMCID: PMC122221
46. Felix K, Rockwood LD, Pretsch W, Nair J, Bartsch H, Bornkamm GW, Janz S. Moderate G6PD deficiency increases mutation rates in the brain of mice. Free Radic Biol Med. 2002 Apr 01;32(7):663-73.
47. Kovalchuk AL, Janz S. Isotype switch-mediated CH deletions are a recurrent feature of Myc/CH translocations in peritoneal plasmacytomas in mice. Int J Cancer. 2002 Oct 10;101(5):423-6.
48. Rockwood LD, Torrey TA, Kim JS, Coleman AE, Kovalchuk AL, Xiang S, Ried T, Morse HC 3rd, Janz S. Genomic instability in mouse Burkitt lymphoma is dominated by illegitimate genetic recombinations, not point mutations. Oncogene. 2002 Oct 17;21(47):7235-40.
49. Felix K, Rockwood LD, Pretsch W, Bornkamm GW, Janz S. Redox imbalance and mutagenesis in spleens of mice harboring a hypomorphic allele of Gpdx(a) encoding glucose 6-phosphate dehydrogenase. Free Radic Biol Med. 2003 Jan 15;34(2):226-32.
50. Felix K, Rolink A, Melchers F, Janz S. Bcl-2 reduces mutant rates in a transgenic lacZ reporter gene in mouse pre-B lymphocytes. Mutat Res. 2003 Jan 28;522(1-2):135-44.
51. Janz S, Potter M, Rabkin CS. Lymphoma- and leukemia-associated chromosomal translocations in healthy individuals. Genes Chromosomes Cancer. 2003 Mar;36(3):211-23.
52. Hausmann M, Winkler R, Hildenbrand G, Finsterle J, Weisel A, Rapp A, Schmitt E, Janz S, Cremer C. COMBO-FISH: specific labeling of nondenatured chromatin targets by computer-selected DNA oligonucleotide probe combinations. Biotechniques. 2003 Sep;35(3):564-70, 572-7.
53. Rockwood LD, Nussenzweig A, Janz S. Paradoxical decrease in mutant frequencies and chromosomal rearrangements in a transgenic lacZ reporter gene in Ku80 null mice deficient in DNA double strand break repair. Mutat Res. 2003 Aug 28;529(1-2):51-8.
54. Silva S, Kovalchuk AL, Kim JS, Klein G, Janz S. BCL2 accelerates inflammation-induced BALB/c plasmacytomas and promotes novel tumors with coexisting T(12;15) and T(6;15) translocations. Cancer Res. 2003 Dec 15;63(24):8656-63.
55. Felix K, Polack A, Pretsch W, Jackson SH, Feigenbaum L, Bornkamm GW, Janz S. Moderate hypermutability of a transgenic lacZ reporter gene in Myc-dependent inflammation-induced plasma cell tumors in mice. Cancer Res. 2004 Jan 15;64(2):530-7.
56. Rockwood LD, Felix K, Janz S. Elevated presence of retrotransposons at sites of DNA double strand break repair in mouse models of metabolic oxidative stress and MYC-induced lymphoma. Mutat Res. 2004 Apr 14;548(1-2):117-25.
57. Felix K, Gerstmeier S, Kyriakopoulos A, Howard OM, Dong HF, Eckhaus M, Behne D, Bornkamm GW, Janz S. Selenium deficiency abrogates inflammation-dependent plasma cell tumors in mice. Cancer Res. 2004 Apr 15;64(8):2910-7.
58. Cheung WC, Kim JS, Linden M, Peng L, Van Ness B, Polakiewicz RD, Janz S. Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice. J Clin Invest. 2004 Jun;113(12):1763-73. PMCID: PMC420503
59. Silva S, Wiener F, Klein G, Janz S. Location of Myc, Igh, and Igk on Robertsonian fusion chromosomes is inconsequential for Myc translocations and plasmacytoma development in mice, but Rb(6.15)-carrying tumors prefer Igk-Myc inversions over translocations. Genes Chromosomes Cancer. 2005 Apr;42(4):416-26.
60. Zhu D, Qi CF, Morse HC 3rd, Janz S, Stevenson FK. Deregulated expression of the Myc cellular oncogene drives development of mouse "Burkitt-like" lymphomas from naive B cells. Blood. 2005 Mar 01;105(5):2135-7.
61. McNeil N, Kim JS, Ried T, Janz S. Extraosseous IL-6 transgenic mouse plasmacytoma sometimes lacks Myc-activating chromosomal translocation. Genes Chromosomes Cancer. 2005 Jun;43(2):137-46.
62. Park SS, Shaffer AL, Kim JS, duBois W, Potter M, Staudt LM, Janz S. Insertion of Myc into Igh accelerates peritoneal plasmacytomas in mice. Cancer Res. 2005 Sep 01;65(17):7644-52.
63. Janz S. Uncovering MYC's full oncogenic potential in the hematopoietic system. Oncogene. 2005 May 19;24(22):3541-3.
64. Park SS, Kim JS, Tessarollo L, Owens JD, Peng L, Han SS, Tae Chung S, Torrey TA, Cheung WC, Polakiewicz RD, McNeil N, Ried T, Mushinski JF, Morse HC 3rd, Janz S. Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice. Cancer Res. 2005 Feb 15;65(4):1306-15.
65. Han SS, Shaffer AL, Peng L, Chung ST, Lim JH, Maeng S, Kim JS, McNeil N, Ried T, Staudt LM, Janz S. Molecular and cytological features of the mouse B-cell lymphoma line iMycEmu-1. Mol Cancer. 2005 Nov 09;4:40. PMCID: PMC1298327
66. Kim JS, Han SS, Park SS, McNeil N, Janz S. Plasma cell tumour progression in iMycEmu gene-insertion mice. J Pathol. 2006 May;209(1):44-55.
67. Janz S. Distinct MYC thresholds in hematopoietic neoplasia Blood. 15 July 2006;108(2):413.
68. Han SS, Peng L, Chung ST, DuBois W, Maeng SH, Shaffer AL, Sporn MB, Janz S. CDDO-Imidazolide inhibits growth and survival of c-Myc-induced mouse B cell and plasma cell neoplasms. Mol Cancer. 2006 Jun 07;5:22. PMCID: PMC1553469
69. Janz S. Myc translocations in B cell and plasma cell neoplasms. DNA Repair (Amst). 2006 Sep 08;5(9-10):1213-24.
70. Janz S. TCL1-induced germinal center B lymphomas in mice Blood. 15 September 2006;108(6):1791-1792.
71. Qi CF, Zhou JX, Lee CH, Naghashfar Z, Xiang S, Kovalchuk AL, Fredrickson TN, Hartley JW, Roopenian DC, Davidson WF, Janz S, Morse HC 3rd. Anaplastic, plasmablastic, and plasmacytic plasmacytomas of mice: relationships to human plasma cell neoplasms and late-stage differentiation of normal B cells. Cancer Res. 2007 Mar 15;67(6):2439-47.
72. Boylan KL, Gosse MA, Staggs SE, Janz S, Grindle S, Kansas GS, Van Ness BG. A transgenic mouse model of plasma cell malignancy shows phenotypic, cytogenetic, and gene expression heterogeneity similar to human multiple myeloma. Cancer Res. 2007 May 01;67(9):4069-78.
73. Crouch EE, Li Z, Takizawa M, Fichtner-Feigl S, Gourzi P, Montaño C, Feigenbaum L, Wilson P, Janz S, Papavasiliou FN, Casellas R. Regulation of AID expression in the immune response. J Exp Med. 2007 May 14;204(5):1145-56. PMCID: PMC2118564
74. Hirt C, Dölken G, Janz S, Rabkin CS. Distribution of t(14;18)-positive, putative lymphoma precursor cells among B-cell subsets in healthy individuals. Br J Haematol. 2007 Aug;138(3):349-53.
75. Yan Y, Park SS, Janz S, Eckhardt LA. In a model of immunoglobulin heavy-chain (IGH)/MYC translocation, the Igh 3' regulatory region induces MYC expression at the immature stage of B cell development. Genes Chromosomes Cancer. 2007 Oct;46(10):950-9. PMCID: PMC2742353
76. Park ES, Shaughnessy JD Jr, Gupta S, Wang H, Lee JS, Woo HG, Zhan F, Owens JD Jr, Potter M, Janz S, Mushinski JF. Gene expression profiling reveals different pathways related to Abl and other genes that cooperate with c-Myc in a model of plasma cell neoplasia. BMC Genomics. 2007 Aug 31;8:302. PMCID: PMC2040348
77. Fujita K, Janz S. Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF. Mol Cancer. 2007 Oct 30;6:71. PMCID: PMC2173906
78. Kovalchuk AL, duBois W, Mushinski E, McNeil NE, Hirt C, Qi CF, Li Z, Janz S, Honjo T, Muramatsu M, Ried T, Behrens T, Potter M. AID-deficient Bcl-xL transgenic mice develop delayed atypical plasma cell tumors with unusual Ig/Myc chromosomal rearrangements. J Exp Med. 2007 Nov 26;204(12):2989-3001. PMCID: PMC2118515
79. Rabkin CS, Janz S. Overview of mechanisms and consequences of chromosomal translocation. J Natl Cancer Inst Monogr. 2008(39):1.
80. Janz S. Genetic and environmental cofactors of Myc translocations in plasma cell tumor development in mice. J Natl Cancer Inst Monogr. 2008(39):37-40.
81. Rabkin CS, Hirt C, Janz S, Dölken G. t(14;18) Translocations and risk of follicular lymphoma. J Natl Cancer Inst Monogr. 2008(39):48-51. PMCID: PMC6948841
82. Rabkin CS, Janz S. Mechanisms and consequences of chromosomal translocation. Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):1849-51. PMCID: PMC2562255
83. Khuda SE, Loo WM, Janz S, Van Ness B, Erickson LD. Deregulation of c-Myc Confers distinct survival requirements for memory B cells, plasma cells, and their progenitors. J Immunol. 2008 Dec 01;181(11):7537-49. PMCID: PMC2841033
84. Schüler F, Dölken L, Hirt C, Kiefer T, Berg T, Fusch G, Weitmann K, Hoffmann W, Fusch C, Janz S, Rabkin CS, Dölken G. Prevalence and frequency of circulating t(14;18)-MBR translocation carrying cells in healthy individuals. Int J Cancer. 2009 Feb 15;124(4):958-63. PMCID: PMC4216731
85. Rutsch S, Neppalli VT, Shin DM, DuBois W, Morse HC 3rd, Goldschmidt H, Janz S. IL-6 and MYC collaborate in plasma cell tumor formation in mice. Blood. 2010 Mar 04;115(9):1746-54. PMCID: PMC2832814
86. Zingone A, Cultraro CM, Shin DM, Bean CM, Morse HC 3rd, Janz S, Kuehl WM. Ectopic expression of wild-type FGFR3 cooperates with MYC to accelerate development of B-cell lineage neoplasms. Leukemia. 2010 Jun;24(6):1171-8. PMCID: PMC3118571
87. Han SS, Yun H, Son DJ, Tompkins VS, Peng L, Chung ST, Kim JS, Park ES, Janz S. NF-kappaB/STAT3/PI3K signaling crosstalk in iMyc E mu B lymphoma. Mol Cancer. 2010 Apr 30;9:97. PMCID: PMC2876994
88. de Jong D, Janz S. Anaplastic plasmacytoma of mouse--establishing parallels between subtypes of mouse and human plasma cell neoplasia. J Pathol. 2010 Jul;221(3):242-7. PMCID: PMC3118561
89. Takizawa M, Kim JS, Tessarollo L, McNeil N, Waldschmidt TJ, Casellas R, Ried T, Janz S. Genetic reporter system for oncogenic Igh-Myc translocations in mice. Oncogene. 2010 Jul 15;29(28):4113-20. PMCID: PMC3108853
90. Lee EC, Fitzgerald M, Bannerman B, Donelan J, Bano K, Terkelsen J, Bradley DP, Subakan O, Silva MD, Liu R, Pickard M, Li Z, Tayber O, Li P, Hales P, Carsillo M, Neppalli VT, Berger AJ, Kupperman E, Manfredi M, Bolen JB, Van Ness B, Janz S. Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies. Clin Cancer Res. 2011 Dec 01;17(23):7313-23. PMCID: PMC3443972
91. LeGrand J, Park ES, Wang H, Gupta S, Owens JD Jr, Nelson PJ, DuBois W, Bair T, Janz S, Mushinski JF. Global gene expression profiling in mouse plasma cell tumor precursor and bystander cells reveals potential intervention targets for plasma cell neoplasia. Blood. 2012 Jan 26;119(4):1018-28. PMCID: PMC3271714
92. Suthaus J, Stuhlmann-Laeisz C, Tompkins VS, Rosean TR, Klapper W, Tosato G, Janz S, Scheller J, Rose-John S. HHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice. Blood. 2012 May 31;119(22):5173-81. PMCID: PMC3370672
93. Qi CF, Kim YS, Xiang S, Abdullaev Z, Torrey TA, Janz S, Kovalchuk AL, Sun J, Chen D, Cho WC, Gu W, Morse Iii HC. Characterization of ARF-BP1/HUWE1 interactions with CTCF, MYC, ARF and p53 in MYC-driven B cell neoplasms. Int J Mol Sci. 2012;13(5):6204-6219. PMCID: PMC3382761
94. Bommert KS, Effenberger M, Leich E, Küspert M, Murphy D, Langer C, Moll R, Janz S, Mottok A, Weissbach S, Rosenwald A, Bargou R, Bommert K. The feed-forward loop between YB-1 and MYC is essential for multiple myeloma cell survival. Leukemia. 2013 Feb;27(2):441-50. PMCID: PMC4047128
95. Han SS, Son DJ, Yun H, Kamberos NL, Janz S. Piperlongumine inhibits proliferation and survival of Burkitt lymphoma in vitro. Leuk Res. 2013 Feb;37(2):146-54. PMCID: PMC3551475
96. Stessman HA, Baughn LB, Sarver A, Xia T, Deshpande R, Mansoor A, Walsh SA, Sunderland JJ, Dolloff NG, Linden MA, Zhan F, Janz S, Myers CL, Van Ness BG. Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model. Mol Cancer Ther. 2013 Jun;12(6):1140-50. PMCID: PMC4076840
97. Stessman HA, Mansoor A, Zhan F, Janz S, Linden MA, Baughn LB, Van Ness B. Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib. Leukemia. 2013 Oct;27(10):2075-7. PMCID: PMC4053943
98. Han SS, Tompkins VS, Son DJ, Kamberos NL, Stunz LL, Halwani A, Bishop GA, Janz S. Piperlongumine inhibits LMP1/MYC-dependent mouse B-lymphoma cells. Biochem Biophys Res Commun. 2013 Jul 12;436(4):660-5. PMCID: PMC3749779
99. Janz S. Waldenström macroglobulinemia: clinical and immunological aspects, natural history, cell of origin, and emerging mouse models. ISRN Hematol. 2013 Sep 09;2013:815325. PMCID: PMC3782845
100. Duncan K, Rosean TR, Tompkins VS, Olivier A, Sompallae R, Zhan F, Tricot G, Acevedo MR, Ponto LL, Walsh SA, Tygrett LT, Berger AJ, Waldschmidt T, Morse HC 3rd, Sunderland JJ, Janz S. (18)F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib. Blood Cancer J. 2013 Nov 29;3(11):e165. PMCID: PMC3880444
101. Tompkins VS, Han SS, Olivier A, Syrbu S, Bair T, Button A, Jacobus L, Wang Z, Lifton S, Raychaudhuri P, Morse HC 3rd, Weiner G, Link B, Smith BJ, Janz S. Identification of candidate B-lymphoma genes by cross-species gene expression profiling. PLoS One. 2013;8(10):e76889. PMCID: PMC3793908
102. Zhou W, Yang Y, Gu Z, Wang H, Xia J, Wu X, Zhan X, Levasseur D, Zhou Y, Janz S, Tricot G, Shi J, Zhan F. ALDH1 activity identifies tumor-initiating cells and links to chromosomal instability signatures in multiple myeloma. Leukemia. 2014 May;28(5):1155-8. PMCID: PMC4018236
103. Ontiveros EP, Halwani A, Stunz LL, Kamberos N, Olivier AK, Janz S, Bishop GA. A new model of LMP1-MYC interaction in B cell lymphoma. Leuk Lymphoma. 2014 Dec;55(12):2917-23. PMCID: PMC4207734
104. Rosean TR, Tompkins VS, Tricot G, Holman CJ, Olivier AK, Zhan F, Janz S. Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma. Immunol Res. 2014 Aug;59(1-3):188-202. PMCID: PMC4209159
105. Eckers JC, Kalen AL, Sarsour EH, Tompkins VS, Janz S, Son JM, Doskey CM, Buettner GR, Goswami PC. Forkhead box M1 regulates quiescence-associated radioresistance of human head and neck squamous carcinoma cells. Radiat Res. 2014 Oct;182(4):420-9. PMCID: PMC4221113
106. Yang Y, Zhou W, Xia J, Gu Z, Wendlandt E, Zhan X, Janz S, Tricot G, Zhan F. NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma. Oncotarget. 2014 Dec 15;5(23):11986-97. PMCID: PMC4322982
107. Reed SM, Hagen J, Muniz VP, Rosean TR, Borcherding N, Sciegienka S, Goeken JA, Naumann PW, Zhang W, Tompkins VS, Janz S, Meyerholz DK, Quelle DE. NIAM-deficient mice are predisposed to the development of proliferative lesions including B-cell lymphomas. PLoS One. 2014;9(11):e112126. PMCID: PMC4231569
108. Rosean TR, Tompkins VS, Olivier AK, Sompallae R, Norian LA, Morse HC 3rd, Waldschmidt TJ, Janz S. The tumor microenvironment is the main source of IL-6 for plasma cell tumor development in mice. Leukemia. 2015 Jan;29(1):233-7. PMCID: PMC4286499
109. Yang Y, Shi J, Gu Z, Salama ME, Das S, Wendlandt E, Xu H, Huang J, Tao Y, Hao M, Franqui R, Levasseur D, Janz S, Tricot G, Zhan F. Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma. Cancer Res. 2015 Feb 01;75(3):594-604. PMCID: PMC4384656
110. Han SS, Tompkins VS, Son DJ, Han S, Yun H, Kamberos NL, Dehoedt CL, Gu C, Holman C, Tricot G, Zhan F, Janz S. CDKN1A and FANCD2 are potential oncotargets in Burkitt lymphoma and multiple myeloma. Exp Hematol Oncol. 2015;4:9. PMCID: PMC4383050
111. Zhang L, Blackwell K, Workman LM, Chen S, Pope MR, Janz S, Habelhah H. RIP1 Cleavage in the Kinase Domain Regulates TRAIL-Induced NF-κB Activation and Lymphoma Survival. Mol Cell Biol. 2015 Oct;35(19):3324-38. PMCID: PMC4561725
112. Tompkins VS, Rosean TR, Holman CJ, DeHoedt C, Olivier AK, Duncan KM, Jing X, Foor SD, Acevedo MR, Walsh SA, Tricot G, Zhan F, Janz S. Adoptive B-cell transfer mouse model of human myeloma. Leukemia. 2016 Apr;30(4):962-6. PMCID: PMC4821809
113. Franqui-Machin R, Wendlandt EB, Janz S, Zhan F, Tricot G. Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction? Oncotarget. 2015 Dec 01;6(38):40496-506. PMCID: PMC4747348
114. Gu C, Yang Y, Sompallae R, Xu H, Tompkins VS, Holman C, Hose D, Goldschmidt H, Tricot G, Zhan F, Janz S. FOXM1 is a therapeutic target for high-risk multiple myeloma. Leukemia. 2016 Apr;30(4):873-82. PMCID: PMC4826574
115. Rosean TR, Holman CJ, Tompkins VS, Jing X, Krasowski MD, Rose-John S, Janz S. KSHV-encoded vIL-6 collaborates with deregulated c-Myc to drive plasmablastic neoplasms in mice. Blood Cancer J. 2016 Feb 26;6(2):e398. PMCID: PMC4771969
116. Janz S. Mouse model of MYD88L265P-dependent DLBCL. Blood. 2016 Jun 02;127(22):2660-1.
117. Rabellino A, Melegari M, Tompkins VS, Chen W, Van Ness BG, Teruya-Feldstein J, Conacci-Sorrell M, Janz S, Scaglioni PP. PIAS1 Promotes Lymphomagenesis through MYC Upregulation. Cell Rep. 2016 Jun 07;15(10):2266-2278. PMCID: PMC4899214
118. Tompkins VS, Sompallae R, Rosean TR, Walsh S, Acevedo M, Kovalchuk AL, Han SS, Jing X, Holman C, Rehg JE, Herms S, Sunderland JS, Morse HC, Janz S. Transgenic mouse model of IgM<sup>+</sup> lymphoproliferative disease mimicking Waldenström macroglobulinemia. Blood Cancer J. 2016 Nov 04;6(11):e488. PMCID: PMC5148059
119. Hao M, Franqui-Machin R, Xu H, Shaughnessy J Jr, Barlogie B, Roodman D, Quelle DE, Janz S, Tomasson MH, Sanderson RD, Qiu L, Frech I, Tricot G, Zhan F. NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma. Leukemia. 2017 Jul;31(7):1648-1650. PMCID: PMC5508075
120. Wang W, Zhang Y, Chen R, Tian Z, Zhai Y, Janz S, Gu C, Yang Y. Chromosomal instability and acquired drug resistance in multiple myeloma. Oncotarget. 2017 Sep 29;8(44):78234-78244. PMCID: PMC5652852
121. Gu C, Holman C, Sompallae R, Jing X, Tomasson M, Hose D, Seckinger A, Zhan F, Tricot G, Goldschmidt H, Yang Y, Janz S. Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome. Blood Cancer J. 2018 Feb 15;8(2):22. PMCID: PMC5814454
122. Gu C, Jing X, Holman C, Sompallae R, Zhan F, Tricot G, Yang Y, Janz S. Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma. BMC Cancer. 2018 Nov 21;18(1):1152. PMCID: PMC6249818
123. Janz S. New wrinkle on deubiquitination in B-cell lymphoma. Blood. 2018 Dec 13;132(24):2529-2530.
124. Ali M, Kowkuntla S, Delloro DJ, Galambos C, Hathi D, Janz S, Shokeen M, Tripathi C, Xu H, Yuk J, Zhan F, Tomasson MH, Bates ML. Chronic intermittent hypoxia enhances disease progression in myeloma-resistant mice. Am J Physiol Regul Integr Comp Physiol. 2019 May 01;316(5):R678-R686. PMCID: PMC6589607
125. Dhakal B, Janz S. Myeloma sleeper agent in myeloid disguise. Blood. 2019 Jul 04;134(1):3-4.
126. Sun F, Cheng Y, Walsh SA, Acevedo MR, Jing X, Han SS, Pisano MD, Tomasson MH, Lichtenstein AK, Zhan F, Hari P, Janz S. Osteolytic disease in IL-6 and Myc dependent mouse model of human myeloma. Haematologica. 2020 Mar;105(3):e111-e115. PMCID: PMC7049347
127. Xiu Y, Dong Q, Fu L, Bossler A, Tang X, Boyce B, Borcherding N, Leidinger M, Sardina JL, Xue HH, Li Q, Feldman A, Aifantis I, Boccalatte F, Wang L, Jin M, Khoury J, Wang W, Hu S, Yuan Y, Wang E, Yuan J, Janz S, Colgan J, Habelhah H, Waldschmidt T, Müschen M, Bagg A, Darbro B, Zhao C. Coactivation of NF-κB and Notch signaling is sufficient to induce B-cell transformation and enables B-myeloid conversion. Blood. 2020 Jan 09;135(2):108-120. PMCID: PMC6952829
128. Dhakal B, Narra RK, Giri S, Szabo A, Smunt TL, Ghose S, Pathak LK, Aryal M, Hamadani M, Chhabra S, Janz S, D'Souza A, Hari PN. Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta-analysis of phase 3 randomized controlled trials. Cancer. 2020 Jun 15;126(12):2791-2801.
129. Janz S. MYC needs MNT to drive B cells over the edge. Blood. 2020 Mar 26;135(13):977-978. PMCID: PMC7099328
130. Dhakal B, Miller S, Rein L, Pathak LK, Gloria L, Szabo A, Giri S, Chhabra S, Hamadani M, Paner A, Padmanabhan A, Janz S, D'Souza A, Hari P. Trends in the use of therapeutic plasma exchange in multiple myeloma. J Clin Apher. 2020 Aug;35(4):307-315.
131. Williams A, Baruah D, Patel J, Szabo A, Chhabra S, Dhakal B, Hari P, Janz S, Stolley M, D'Souza A. Prevalence and significance of sarcopenia in multiple myeloma patients undergoing autologous hematopoietic cell transplantation. Bone Marrow Transplant. 2021 Jan;56(1):225-231. PMCID: PMC7855279
132. Cheng Y, Sun F, D'Souza A, Dhakal B, Pisano M, Chhabra S, Stolley M, Hari P, Janz S. Autonomic nervous system control of multiple myeloma. Blood Rev. 2021 Mar;46:100741. PMCID: PMC7876165
133. Dou R, Qian J, Wu W, Zhang Y, Yuan Y, Guo M, Wei R, Yang S, Jurczyszyn A, Janz S, Beksac M, Gu C, Yang Y. Suppression of steroid 5α-reductase type I promotes cellular apoptosis and autophagy via PI3K/Akt/mTOR pathway in multiple myeloma. Cell Death Dis. 2021 Feb 24;12(2):206. PMCID: PMC7904855
134. Jiang F, Tang X, Tang C, Hua Z, Ke M, Wang C, Zhao J, Gao S, Jurczyszyn A, Janz S, Beksac M, Zhan F, Gu C, Yang Y. HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA. J Hematol Oncol. 2021 Apr 01;14(1):54. PMCID: PMC8017865
135. Gu C, Wang W, Tang X, Xu T, Zhang Y, Guo M, Wei R, Wang Y, Jurczyszyn A, Janz S, Beksac M, Zhan F, Seckinger A, Hose D, Pan J, Yang Y. CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma. Mol Cancer. 2021 Jun 05;20(1):84. PMCID: PMC8178856
136. Li C, Xia J, Franqui-Machin R, Chen F, He Y, Ashby TC, Teng F, Xu H, Liu D, Gai D, Johnson SK, van Rhee F, Janz S, Shaughnessy JD Jr, Tricot G, Frech I, Zhan F. TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies. J Clin Invest. 2021 Jul 15;131(14). PMCID: PMC8279583
137. Pisano M, Cheng Y, Sun F, Dhakal B, D'Souza A, Chhabra S, Knight JM, Rao S, Zhan F, Hari P, Janz S. Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma. Front Immunol. 2021;12:667054. PMCID: PMC8206561
138. Sun F, Cheng Y, Riordan JD, Dupuy A, Dubois W, Pisano M, Dong J, Mock B, Zhan F, Hari P, Janz S. WDR26 and MTF2 are therapeutic targets in multiple myeloma. J Hematol Oncol. 2021 Dec 07;14(1):203. PMCID: PMC8650373
139. Shi Y, Sun F, Cheng Y, Holmes B, Dhakal B, Gera JF, Janz S, Lichtenstein A. Critical Role for Cap-Independent c-MYC Translation in Progression of Multiple Myeloma. Mol Cancer Ther. 2022 Apr 01;21(4):502-510. PMCID: PMC8983490
140. Dong J, Garacci Z, Buradagunta CS, D'Souza A, Mohan M, Cunningham A, Janz S, Dhakal B, Thrift AP, Hari P. Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study. Blood Cancer J. 2022 Feb 24;12(2):34. PMCID: PMC8873507
141. Buradagunta CS, Garacci Z, D'Souza A, Dhakal B, Devata S, Janz S, Thrift AP, Hari P, Stolley M, Dong J. Socioeconomic disadvantage contributes to ethnic disparities in multiple myeloma survival: a matched cohort study. Blood Cancer J. 2022 May 25;12(5):82. PMCID: PMC9132975
142. Cheng Y, Sun F, Thornton K, Jing X, Dong J, Yun G, Pisano M, Zhan F, Kim SH, Katzenellenbogen JA, Katzenellenbogen BS, Hari P, Janz S. FOXM1 regulates glycolysis and energy production in multiple myeloma. Oncogene. 2022 Aug;41(32):3899-3911. PMCID: PMC9355869
143. Wei R, Cui X, Min J, Lin Z, Zhou Y, Guo M, An X, Liu H, Janz S, Gu C, Wang H, Yang Y. NAT10 promotes cell proliferation by acetylating CEP170 mRNA to enhance translation efficiency in multiple myeloma Acta Pharmaceutica Sinica B. August 2022;12(8):3313-3325.
144. Mohan M, Rein LE, Thalambedu N, Ogunsesan Y, Hussain M, Sethi J, Khan F, Gundarlapalli S, Yarlagadda L, Dhakal B, Price M, Shirey M, Warner D, Thanendrarajan S, Janz S, Radhakrishnan SV, Al Hadidi S, Szabo A, D'Souza A, Zangari M, van Rhee F, Chhabra S, Schinke C. Corneal toxicity with belantamab mafodotin: Multi-institutional real-life experience. Am J Hematol. 2022 Dec;97(12):E451-E453.
145. D'Souza A, Brazauskas R, Teng BQ, Yun G, Uttley H, Dong J, Dwinell MB, Pasquini MC, Giralt S, Landau H, Stadtmauer E, Krishnan A, Janz S. DNA methylation in circulating leukocytes is a novel biomarker in multiple myeloma. Bone Marrow Transplant. 2023 Mar;58(3):334-336.
146. Al Hadidi S, Szabo A, Esselmann J, Hammons L, Hussain M, Ogunsesan Y, Thalambedu N, Khan F, Sethi J, Janardan A, Radhakrishnan SV, Thanendrarajan S, Schinke C, Dhakal B, Janz S, Chhabra S, D'Souza A, Zangari M, van Rhee F, Mohan M. Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy. Bone Marrow Transplant. 2023 Apr;58(4):443-445.
147. Kleman A, Singavi A, Pommert L, Mathison AJ, Hari P, Dhakal B, Mohan M, Janz S, Knight JM, Shah MV, Schinke C, Burns R, Steinhardt GF, Rao S, Carlson K. A timeline of genetic variant enrichment: from multiple myeloma diagnosis to myeloma-associated myeloid malignancy. Blood Adv. 2023 Sep 26;7(18):5549-5553. PMCID: PMC10514068
148. Mohan M, Janz S, Brazauskas R, Dwinell MB, Teng BQ, Yun G, Dong J, Pasquini MC, Giralt S, Landau H, Stadtmauer E, Krishnan A, D'Souza A. Increased CXCL10 is seen at 1-year after autologous hematopoietic cell transplantation in multiple myeloma patients on maintenance lenalidomide therapy. Bone Marrow Transplant. 2023 Aug;58(8):953-955. PMCID: PMC10555486
149. Sun F, Cheng Y, Ying J, Mery D, Al Hadidi S, Wanchai V, Siegel ER, Xu H, Gai D, Ashby TC, Bailey C, Chen JR, Schinke C, Thanendrarajan S, Zangari M, Janz S, Barlogie B, Van Rhee F, Tricot G, Shaughnessy JD Jr, Zhan F. A gene signature can predict risk of MGUS progressing to multiple myeloma. J Hematol Oncol. 2023 Jun 29;16(1):70. PMCID: PMC10308756
150. Pisano MD, Sun F, Cheng Y, Parashar D, Zhou V, Jing X, Sompallae R, Abrudan J, Zimmermann MT, Mathison A, Janz S, Pufall MA. IL6Myc mouse is an immunocompetent model for the development of aggressive multiple myeloma. Haematologica. 2023 Dec 01;108(12):3372-3383. PMCID: PMC10690922
151. Hammons L, Szabo A, Janardan A, Bhatlapenumarthi V, Annyapu E, Dhakal B, Al Hadidi S, Radhakrishnan SV, Narra R, Bhutani D, Thanendrarajan S, Janz S, Zangari M, Lentzsch S, Van Rhee F, Crescencio JCR, D'Souza A, Chakraborty R, Mohan M, Schinke C. The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma. Haematologica. 2024 Mar 01;109(3):906-914. PMCID: PMC10905074
152. Cheng Y, Sun F, Alapat DV, Wanchai V, Mery D, Guo W, Cao H, Zhu Y, Ashby C, Bauer MA, Nookaew I, Siegel ER, Ying J, Chen JR, Gai D, Peng B, Xu H, Bailey C, Al Hadidi S, Schinke C, Thanendrarajan S, Zangari M, Chesi M, Bergsagel PL, van Rhee F, Janz S, Tricot G, Shaughnessy JD Jr, Zhan F. High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma. Cell Rep Med. 2023 Oct 17;4(10):101214. PMCID: PMC10591052
153. Mohan M, Kothari A, Verhagen N, Shreenivas A, Radhakrishnan SV, Dhakal B, Figueroa-Castro C, Chhabra S, Janz S, Pasquini M, Hamadani M, Szabo A, D'Souza A, N3C consortium. Blood and marrow transplant within 4 weeks of SARS-CoV-2 infection is associated with increased risk of mortality: a National COVID Cohort Collaborative (N3C) Study. Bone Marrow Transplant. 2024 Jan;59(1):121-124.
154. Buradagunta CS, Arsang-Jang S, Massat B, Thapa B, Patek V, D'Souza A, Auer P, Urrutia R, Janz S, Dhakal B, Hari P, Dong J. Identification of novel loci for multiple myeloma when comparing with its precursor condition monoclonal gammopathy of unknown significance. Leukemia. 2024 Feb;38(2):383-385. PMCID: PMC11326531
155. Gu C, Wang W, Tang X, Xu T, Zhang Y, Guo M, Wei R, Wang Y, Jurczyszyn A, Janz S, Beksac M, Zhan F, Seckinger A, Hose D, Pan J, Yang Y. CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma Molecular Cancer. December 2021;20(1).
156. Rabkin CS, Janz S, Lash A, Coleman AE, Musaba E, Liotta L, Biggar RJ, Zhuang Z. Monoclonal origin of multicentric Kaposi's sarcoma lesions. N Engl J Med. 1997 Apr 03;336(14):988-93.
157. Coleman AE, Forest ST, McNeil N, Kovalchuk AL, Ried T, Janz S. Cytogenetic analysis of the bipotential murine pre-B cell lymphoma, P388, and its derivative macrophage-like tumor, P388D1, using SKY and CGH. Leukemia. 1999 Oct;13(10):1592-600.
158. Felix K, Janz S, Pitha J, Williams JA, Mushinski EB, Bornkamm GW, Potter M. Cytotoxicity and membrane damage in vitro by inclusion complexes between gamma-cyclodextrin and siloxanes. Curr Top Microbiol Immunol. 1996;210:93-9.
159. Li JR, Arsang-Jang S, Cheng Y, Sun F, D'Souza A, Dhakal B, Hari P, Huang Q, Auer P, Li Y, Urrutia R, Zhan F, Shaughnessy JD Jr, Janz S, Dong J, Cheng C. Enhancing prognostic power in multiple myeloma using a plasma cell signature derived from single-cell RNA sequencing. Blood Cancer J. 2024 Mar 06;14(1):38. PMCID: PMC10915134
160. Janz S, Shacter E and Herrmann A. The plasmacytomagenic agent pristane (2,6,10,14-tetramethylpentadecane) solubilized by -cyclodextrin promotes fusion between enveloped viruses and cell membranes as assessed by fluorescence dequenching analysis. Cancer Biochem Biophys 14:1-10, 1994.
161. Müller JR, Potter M and Janz S. Differences in the molecular structure of c-myc- activating recombinations in murine plasmacytomas and precursor cells. Proc Natl Acad Sci USA 91:12066-12070, 1994.
162. Janz S and Roschke VV. Completion of the DNA sequence determination of the Igh2 locus of the mouse: the 5'-IA region. Immunogenetics 43(1-2):101-104, 1996.
163. Coleman AE, Schröck E, Weaver Z, du Manoir S, Ferguson-Smith MA, Ried T and Janz S. Multicolor spectral karyotyping (SKY) in T(12;15)-positive BALB/c plasmacytomas. Cancer Res 57:4585-4592, 1997.
164. Kovalchuk AL, Kishimoto T. and Janz S. IL-6 transgenic BALB/c mice spontaneously develop clones of T(12;15) translocated B cells with genetic exchanges between the upstream flank of C and c-myc. Leukemia 14:1127-1135, 2000.
165. Kovalchuk AL, Kishimoto T. and Janz S. IL-6 transgenic BALB/c mice spontaneously develop clones of T(12;15) translocated B cells with genetic exchanges between the upstream flank of C and c-myc. Leukemia 14:1127-1135, 2000.
166. Kovalchuk AL, Kim JS and Janz S. IgH transposition sensitizes Myc to undergo trans-chromosomal class switch recombination in IL-6 transgenic BALB/c mice. Oncogene 22:2842-2850, 2003.
167. Sood A, Ginty F, Chadwick C, Janz S and Holman C. In situ multiplex immunofluorescence analysis of plasma cell myeloma tissue sections. Amer. J. Clin. Path. 2018, 150(suppl 1):S161-S162.
168. Janz S, Zhan F, Sun F, Cheng Y, Pisano M, Yang Y, Goldschmidt H, Hari P. Germline Risk Contribution to Genomic Instability in Multiple Myeloma. Front Genet. 2019;10:424. PMCID: PMC6518313
169. Gao M, Bai H, Jethava Y, Wu Y, Zhu Y, Yang Y, Xia J, Cao H, Franqui-Machin R, Nadiminti K, Thomas GS, Salama ME, Altevogt P, Bishop G, Tomasson M, Janz S, Shi J, Chen L, Frech I, Tricot G, Zhan F. Identification and Characterization of Tumor-Initiating Cells in Multiple Myeloma. J Natl Cancer Inst. 2020 May 01;112(5):507-515. PMCID: PMC7225664
170. Zhou V, Yu M, Fu J, Janz S, Cui X. Synergistic effect of FOXM1 and BCL-2 inhibition in a preclinical treatment study on multiple myeloma. J Transl Med. 2024 Jul 08;22(1):638. PMCID: PMC11232139
171. Yu M, Zhou V, Pisano MD, Janz S, Cui X. Changes in the immune microenvironment during plasma cell tumor development in the IL6Myc mouse model of human multiple myeloma. Exp Cell Res. 2024 Oct 01;442(2):114273.
172. Wen Z, Wang Y, Fox KC, Bissonnette AM, Moat LF, Kitchner TE, Springstroh K, Kim SH, Sheerar DS, Tanawattanacharoen P, Leon CA, Fagbemi SO, Katzenellenbogen JA, Hebbring SJ, Katzenellenbogen BS, Janz S, Onitilo AA. Inhibition of FOXM1 Synergizes with BH3 Mimetics Venetoclax and Sonrotoclax in Killing Multiple Myeloma Cells through Repressing MYC Pathway. Adv Sci (Weinh). 2025 Oct;12(37):e08822. PMCID: PMC12499415
173. Kasomva K, Yadav K, Janz S, Dhakal B, Rao S. Molecular and immunological determinants of long-term survival in multiple myeloma. Blood Adv. 2025 Oct 28;9(20):5134-5147. PMCID: PMC12550235
 
Books, Chapters, and Reviews
1. Janz S, Jones GM, Müller JR, Potter M. Genomic instability in B-cells and diversity of recombinations that activate c-myc. Curr Top Microbiol Immunol. 1995;194:373-80.
2. Müller JR, Janz S, Potter M. Illegitimate recombinations between c-myc and immunoglobulin loci are remodeled by deletions in mouse plasmacytomas but not in Burkitt's lymphomas. Curr Top Microbiol Immunol. 1995;194:425-9.
3. Janz S, Kovalchuk AL, Müller JR, Potter M. Genetic recombinations between c-myc and Igh mu as precursors for recombinations between c-myc and Igh alpha in BALB/c plasmacytomas. Curr Top Microbiol Immunol. 1997;224:241-50.
4. Felix K, Kelliher K, Bornkamm GW, Janz S. Transgenic shuttle vector assays for assessing oxidative B-cell mutagenesis in vivo. Curr Top Microbiol Immunol. 1999;246:369-75; discussion 376-7.
5. Felix K, Rockwood LD, Janz S. Transgenic shuttle vector assays for determining genetic differences in oxidative B cell mutagenesis in vivo. Methods Enzymol. 2002;353:434-48.
6. Coleman AE, Ried T, Janz S. Recurrent non-reciprocal translocations of chromosome 5 in primary T(12;15)-positive BALB/c plasmacytomas. Curr Top Microbiol Immunol. 1999;246:175-80; discussion 181.
7. Müller J, Brede O and Janz S. A -radiolysis study on the potential involvement of a genotoxic metabolite in pristane induced plasmacytomagenesis. In Mai H, Brede O and Mehnert R (eds). Radiation Interactions. 5th Edition. Central Institute of Isotope and Radiation Research Press, Leipzig, Germany, pp 131-137, 1991.
8. Janz S, Müller J, Shaughnessy J, Potter M. Chromosomal translocations t(12;15) are an early event in murine plasmacytomagenesis. In Melchers F and Potter M (eds). Mechanisms of B cell neoplasia. Editiones Roche, Basel, Switzerland, pp 303-309, 1993.
9. Janz S. Cancer-associated chromosomal translocations in healthy individuals. In Creighton TE (ed). Encyclopedia of Molecular Medicine, John Wiley & Sons, New York, NY, pp 779-782, 2002.
10. Janz S. Plasmacytoma. In Schwab M (ed). Encyclopedia of Cancer, 2nd edition, Springer, ISBN 978-3-540-36847-2, 2009.
11. Janz S. Monoclonal gammopathy of undetermined significance. In Schwab M (ed). Encyclopedia of Cancer, 2nd edition, Springer, ISBN 978-3-540-36847-2, 2009.
12. Janz S, Morse HC III, Teitell MA. Mouse models of human mature B cell lineage neoplasms. In Li S (ed). Mouse models of human blood cancers, Springer, ISBN 978-0-387-69130-5, 179-225, 2008.
13. Janz S. Plasmacytoma. In Schwab M (ed). Encyclopedia of Cancer, 4th edition, Springer, ISBN 978-3-642-16482-8, 2016.
14. Janz S. Monoclonal gammopathy of undetermined significance. In Schwab M (ed). Encyclopedia of Cancer, 4th edition, Springer, ISBN 978-3-642-16482-8, 2016.
 
Patents
1. Molecular encapsulation and delivery of alkanes to living mammalian cells for risk assessment and pharmaceutical applications. Patent No. 5,321,014. Date of patent, June 14, 1994.